Analyst Price Targets — INVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 2:24 pm | Steve Seedhouse | Cantor Fitzgerald | $32.00 | $23.98 | StreetInsider | Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook |
| February 17, 2026 11:10 am | — | BTIG | $35.00 | $22.70 | TheFly | Innoviva initiated with a Buy at BTIG |
| December 16, 2025 11:11 am | — | H.C. Wainwright | $46.00 | $20.15 | TheFly | Innoviva price target raised to $46 from $45 at H.C. Wainwright |
| September 30, 2025 9:12 am | — | Goldman Sachs | $17.00 | $19.03 | TheFly | Innoviva initiated with a Sell at Goldman Sachs |
| August 11, 2025 11:53 am | Trevor Allred | Oppenheimer | $35.00 | $19.93 | Benzinga | This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday |
| March 7, 2025 12:00 pm | — | Scotiabank | $55.00 | $17.64 | TheFly | Innoviva initiated with an Outperform at Scotiabank |
| August 8, 2022 9:38 am | — | Morgan Stanley | $13.00 | $14.72 | Benzinga | Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $13 |
| July 15, 2022 11:05 am | — | Morgan Stanley | $12.00 | $14.37 | Benzinga | Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $12 |
Latest News for INVA
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to
The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.
Innoviva, Inc. (NASDAQ: INVA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $20.50 and traded as high as $23.15. Innoviva shares last traded at $23.02, with a volume of 450,806 shares. Analyst Upgrades and Downgrades
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INVA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.